Patient-rated suitability of a new electronic device (Rebismart™) for subcutaneous injection of interferon beta-1a in relapsing multiple sclerosis: an international, multicentre, single-arm, open-label, 12-week, Phase IIIB study. Poster presented at the 25th ECTRIMS - Devonshire, V (Düsseldorf, Germany, 2009)
9–12 September